fashion -WSS

fashion

author：comprehensive 2025-09-29 22:53:22 - browse：18969

Christine Kao/STAT

The biggest enticement that large pharmacy benefit managers offer to the employers that hire them is drug rebates — a steady stream of money sent back to their clients, a tangible symbol of the discounts that PBMs are able to wrangle out of pharmaceutical companies.

PBMs, the middlemen of drug pricing negotiations, also claim portions of those lucrative rebates for themselves. So when new market developments threaten to diminish or wipe away that revenue stream, PBMs find crafty ways to keep as much of those dollars as possible — often at the expense of employers.

One such case occurred last year, when a wave of Humira biosimilars entered the market and drug companies slashed the list prices of their insulin products. CVS Caremark, the PBM owned by CVS Health that oversees the prescription drug benefits of 103 million people, told its employer clients that it anticipated “more lower-cost products (including specialty biosimilars) may become preferred products” on its lists of approved drugs for 2024, according to documents obtained by STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Judge rejects Trump's counterclaim against E. Jean Carroll

WSS

The Biogen Aduhelm mess could happen again

Why CTE doesn’t keep Americans from enjoying the Super Bowl

AI gets buy

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Top private equity targets in 2023: cardiology, clinical trials, lasers

Astronauts get first look at the spacecraft that will fly them around the moon

focus

fashion

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

Ohioans vote in high

Heart attack and stroke risk calculators need revising

CDC launches VaccineFinder tool to locate Covid

Anesthesiologist group: stop taking Ozempic before surgery

Choosing scientific sides in the fight against Alzheimer's

Tori Bowie and the unacceptable rates of Black maternal death

Medicare Advantage plans can’t deny care with AI, CMS warns

Novavax promises a turnaround & Lilly roils the obesity market

An Ebola outbreak presents a new mystery involving children

hotspot

Novo Holdings to buy drug manufacturer Catalent in $16.5B deal

Ohioans vote in high

Judge rejects Trump's counterclaim against E. Jean Carroll

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Why Novartis is going to walk from its acquisition of MorphoSys

The painfully weak evidence on taking collagen to treat arthritis

explore

hotspot

hotspot

focus